secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001493152-25-018454
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem extends Adjuvant convertible note maturity to April 2026; prepayment restricted
--------------------------------------------------------------------------------

- Notes become due on earliest of: 6 months after Oct 13, 2025 (April 13, 2026), change of control, or acceleration.
- No prepayment permitted before April 13, 2026 without Adjuvant's written consent.
- Amendment dated October 13, 2025 modifies the October 2020 Securities Purchase Agreement.
- Adjuvant Global Health Technology Fund holds the convertible promissory notes covered by the amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/0001493152-25-018454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer